Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study

BACKGROUND: We evaluated the safety and efficacy of the anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) brigatinib in Japanese patients with TKI-naive ALK-positive non-small cell lung cancer (NSCLC) from the phase 2, open-label, single-arm, multicenter J-ALTA study. METHODS: In the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugawara, Shunichi, Kondo, Masashi, Yokoyama, Toshihide, Kumagai, Toru, Nishio, Makoto, Goto, Koichi, Nakagawa, Kazuhiko, Seto, Takashi, Yamamoto, Nobuyuki, Kudou, Kentarou, Asato, Takayuki, Zhang, Pingkuan, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700635/
https://www.ncbi.nlm.nih.gov/pubmed/36036294
http://dx.doi.org/10.1007/s10147-022-02232-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700635/
https://www.ncbi.nlm.nih.gov/pubmed/36036294
http://dx.doi.org/10.1007/s10147-022-02232-7

Ejemplares similares